Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Contrast-Enhanced Imaging for Diagnosing Bladder Cancer Stage in Patients Undergoing Bladder Surgery

Trial Status: active

This clinical trial is evaluating whether a single magnetic resonance imaging scan with contrast agents gadobutrol and ferumoxytol can accurately diagnose the stage of bladder cancer in patients who are scheduled to have a resection (transurethral resection of the bladder tumor [TURBT]) or a complete removal of the bladder (cystectomy). Magnetic resonance imaging is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. These pictures can show the difference between normal and diseased tissue. Gadobutrol and ferumoxytol are contrast agents that are injected into the body and taken up by certain tissues, making the tissues easier to see in imaging scans. Giving gadobutrol and ferumoxytol before magnetic resonance imaging may work better at diagnosing the stage of bladder cancer in patients who are scheduled to have TURBT or a cystectomy.

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.